Quick Answer
ACTUATE THERAPEUTICS, INC. reported R&D Expense of $10.29 million for fiscal year 2025.
ACTUATE THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.29M | -44.9% |
| 2024 | $18.68M | -14.0% |
| 2023 | $21.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.18M | -42.0% | -21.2% |
| June 30, 2025 | $2.76M | -36.8% | -14.1% |
| March 31, 2025 | $3.22M | -53.1% | -14.3% |
| September 30, 2024 | $3.76M | -34.8% | -14.1% |
| June 30, 2024 | $4.37M | -8.5% | -36.3% |
| March 31, 2024 | $6.86M | — | +19.1% |
| September 30, 2023 | $5.76M | — | +20.6% |
| June 30, 2023 | $4.78M | — | — |
- ACTUATE THERAPEUTICS, INC. showed a decrease of -44.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, ACTUATE THERAPEUTICS, INC.’s r&d expense has declined by 52.6% (from $21.71 million to $10.29 million).
- The most recent figure is from ACTUATE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: